| Year |
Citation |
Score |
| 2019 |
Wilbraham D, Berg PH, Tsai M, Liffick E, Loo LS, Doty EG, Sellers E. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study. Journal of Clinical Pharmacology. PMID 31745991 DOI: 10.1002/Jcph.1543 |
0.418 |
|
| 2018 |
Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy & Behavior : E&B. 88: 162-171. PMID 30286443 DOI: 10.1016/J.Yebeh.2018.07.027 |
0.335 |
|
| 2018 |
Sellers EM. Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2: Optimizing the Design of Human Abuse Potential Studies. Journal of Clinical Psychopharmacology. PMID 29360651 DOI: 10.1097/Jcp.0000000000000838 |
0.321 |
|
| 2018 |
Sellers EM. Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 1: Regulatory Context and Risk Management. Journal of Clinical Psychopharmacology. 38: 11-18. PMID 29215386 DOI: 10.1097/Jcp.0000000000000835 |
0.336 |
|
| 2017 |
Sellers EM, Romach MK, Leiderman DB. Studies with psychedelic drugs in human volunteers. Neuropharmacology. PMID 29162429 DOI: 10.1016/J.Neuropharm.2017.11.029 |
0.335 |
|
| 2017 |
Schoedel KA, Stockis A, Sellers EM. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users. Epilepsy & Behavior : E&B. PMID 29153631 DOI: 10.1016/J.Yebeh.2017.09.008 |
0.369 |
|
| 2017 |
Sellers EM, Romach MK. Categorization of Abuse Potential-Related Adverse Events. Clinical Pharmacology in Drug Development. PMID 29024490 DOI: 10.1002/Cpdd.394 |
0.361 |
|
| 2017 |
Schoedel KA, Andreas JO, Doty P, Eckhardt K, Sellers EM. Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users. Journal of Clinical Psychopharmacology. PMID 28926353 DOI: 10.1097/Jcp.0000000000000780 |
0.376 |
|
| 2017 |
Sellers EM. Psilocybin: Good Trip or Bad Trip. Clinical Pharmacology and Therapeutics. PMID 28548221 DOI: 10.1002/Cpt.697 |
0.345 |
|
| 2016 |
Kopecky EA, Fleming AB, Levy-Cooperman N, O'Connor M, Sellers E. Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER). Journal of Clinical Pharmacology. PMID 27669664 DOI: 10.1002/Jcph.833 |
0.355 |
|
| 2016 |
Levy-Cooperman N, McIntyre G, Bonifacio L, McDonnell M, Davenport JM, Covington PS, Dove LS, Sellers EM. Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist. The Journal of Pharmacology and Experimental Therapeutics. PMID 27647873 DOI: 10.1124/Jpet.116.236547 |
0.399 |
|
| 2016 |
Sellers EM. Deconstructing Designer Drugs. Clinical Pharmacology and Therapeutics. PMID 27564430 DOI: 10.1002/Cpt.462 |
0.332 |
|
| 2016 |
Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. Journal of Clinical Psychopharmacology. PMID 27253658 DOI: 10.1097/Jcp.0000000000000516 |
0.425 |
|
| 2016 |
Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC. The Effect of an Abuse-Deterrent Opioid Formulation on Opioid Abuse-Related Outcomes in the Post-Marketing Setting. Clinical Pharmacology and Therapeutics. PMID 27170195 DOI: 10.1002/Cpt.390 |
0.333 |
|
| 2015 |
Shram MJ, Silverman B, Ehrich E, Sellers EM, Turncliff R. Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist. Journal of Clinical Psychopharmacology. 35: 242-9. PMID 25928699 DOI: 10.1097/Jcp.0000000000000320 |
0.34 |
|
| 2015 |
Sellers EM, Cruz H, Dingemanse J, Chakraborty B, Schoedel K. Abuse potential of a dual orexin receptor antagonist: A randomized, double-blind, crossover study in recreational drug users Drug and Alcohol Dependence. 146: e93-e94. DOI: 10.1016/J.Drugalcdep.2014.09.622 |
0.344 |
|
| 2015 |
Schoedel K, Levy-Cooperman N, Basseches P, Butterfield K, Hewitt D, Larson P, Troyer M, Sellers EM, de Haes JU. Assessment of human abuse potential of preladenant (a centrally-acting A2A antagonist) compared to phentermine and placebo in recreational stimulant users Drug and Alcohol Dependence. 146: e91. DOI: 10.1016/J.Drugalcdep.2014.09.615 |
0.428 |
|
| 2014 |
Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment. 10: 1161-74. PMID 25061302 DOI: 10.2147/Ndt.S30713 |
0.323 |
|
| 2014 |
Romach MK, Schoedel KA, Sellers EM. Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology. 87: 81-90. PMID 24793872 DOI: 10.1016/J.Neuropharm.2014.04.014 |
0.367 |
|
| 2014 |
Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. Cns Drugs. 28: 361-72. PMID 24627301 DOI: 10.1007/S40263-014-0150-X |
0.323 |
|
| 2014 |
Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. Journal of Clinical Pharmacology. 54: 468-77. PMID 24243216 DOI: 10.1002/Jcph.235 |
0.418 |
|
| 2014 |
Sellers EM, Shram MJ, Schoedel KA. The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond Pharmaceutical Medicine. 28: 317-327. DOI: 10.1007/S40290-014-0067-1 |
0.313 |
|
| 2013 |
Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF. A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. Clinical Pharmacology in Drug Development. 2: 285-94. PMID 27121791 DOI: 10.1002/Cpdd.36 |
0.333 |
|
| 2013 |
Higgins GA, Sellers EM, Fletcher PJ. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends in Pharmacological Sciences. 34: 560-70. PMID 24041919 DOI: 10.1016/J.Tips.2013.08.001 |
0.338 |
|
| 2013 |
Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug and Alcohol Dependence. 130: 13-23. PMID 23415386 DOI: 10.1016/J.Drugalcdep.2012.12.028 |
0.365 |
|
| 2012 |
Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, et al. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain. 153: 2315-24. PMID 22998781 DOI: 10.1016/J.Pain.2012.07.035 |
0.316 |
|
| 2012 |
Pope LE, Schoedel KA, Bartlett C, Sellers EM. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clinical Drug Investigation. 32: e1-15. PMID 22712629 DOI: 10.1007/Bf03261905 |
0.305 |
|
| 2012 |
Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, Endrenyi L. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. Clinical Therapeutics. 34: 1170-81. PMID 22512898 DOI: 10.1016/J.Clinthera.2012.02.010 |
0.314 |
|
| 2012 |
Schoedel KA, Pope LE, Sellers EM. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clinical Drug Investigation. 32: 157-69. PMID 22283559 DOI: 10.2165/11599870-000000000-00000 |
0.382 |
|
| 2012 |
Sellers EM, Romach MK. Pharmacotherapy of alcohol and drug problems. Drug and Alcohol Review. 10: 215-24. PMID 16840051 DOI: 10.1080/09595239100185251 |
0.332 |
|
| 2011 |
Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clinical Pharmacology and Therapeutics. 89: 683-92. PMID 21412231 DOI: 10.1038/Clpt.2011.20 |
0.393 |
|
| 2010 |
Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human abuse potential studies. Drug and Alcohol Dependence. 114: 185-93. PMID 21109365 DOI: 10.1016/J.Drugalcdep.2010.10.002 |
0.413 |
|
| 2010 |
Mansbach RS, Schoedel KA, Kittrelle JP, Sellers EM. The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. Drug and Alcohol Dependence. 112: 173-7. PMID 20817417 DOI: 10.1016/J.Drugalcdep.2010.07.001 |
0.373 |
|
| 2010 |
Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clinical Pharmacology and Therapeutics. 88: 69-78. PMID 20520602 DOI: 10.1038/Clpt.2010.67 |
0.372 |
|
| 2010 |
Zawertailo LA, Tyndale RF, Busto U, Sellers EM. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Human Psychopharmacology. 25: 71-9. PMID 20041473 DOI: 10.1002/Hup.1086 |
0.665 |
|
| 2009 |
Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clinical Drug Investigation. 29: 777-90. PMID 19888784 DOI: 10.2165/11530800-000000000-00000 |
0.32 |
|
| 2009 |
Roth W, Setnik B, Zietsch M, Burst A, Breitenbach J, Sellers E, Brennan D. Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation. International Journal of Pharmaceutics. 368: 72-75. PMID 18992310 DOI: 10.1016/J.Ijpharm.2008.09.052 |
0.329 |
|
| 2009 |
Mwenifumbo JC, Sellers EM, Tyndale RF. Corrigendum to "Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking" [Drug Alcohol Depend. 89/1 (2007) 24-33] (DOI:10.1016/j.drugalcdep.2006.11.012) Drug and Alcohol Dependence. 104: 185. DOI: 10.1016/J.Drugalcdep.2009.04.004 |
0.305 |
|
| 2008 |
McColl SL, Burstein AH, Reeves KR, Billing CB, Stolar M, Sellers EM. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clinical Pharmacology and Therapeutics. 83: 607-14. PMID 18288085 DOI: 10.1038/Sj.Clpt.6100510 |
0.408 |
|
| 2008 |
Schoedel KA, Sellers EM. Assessing abuse liability during drug development: changing standards and expectations. Clinical Pharmacology and Therapeutics. 83: 622-6. PMID 18212799 DOI: 10.1038/Sj.Clpt.6100492 |
0.388 |
|
| 2007 |
Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA, Sellers EM. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. Journal of Clinical Pharmacology. 47: 1476-88. PMID 17962423 DOI: 10.1177/0091270007308615 |
0.357 |
|
| 2007 |
Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. Journal of Clinical Psychopharmacology. 27: 459-67. PMID 17873677 DOI: 10.1097/Jcp.0B013E3181515205 |
0.431 |
|
| 2007 |
Damaj MI, Siu EC, Sellers EM, Tyndale RF, Martin BR. Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. The Journal of Pharmacology and Experimental Therapeutics. 320: 250-7. PMID 17021260 DOI: 10.1124/Jpet.106.111237 |
0.306 |
|
| 2006 |
McColl S, Sellers EM. Research design strategies to evaluate the impact of formulations on abuse liability. Drug and Alcohol Dependence. 83: S52-62. PMID 16554125 DOI: 10.1016/J.Drugalcdep.2006.01.015 |
0.368 |
|
| 2006 |
Sellers EM, Schuster CR. Conference on drug formulations and abuse liability Drug and Alcohol Dependence. 83: S1-S3. DOI: 10.1016/J.Drugalcdep.2006.03.001 |
0.353 |
|
| 2005 |
Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. Journal of Clinical Pharmacology. 45: 1413-21. PMID 16291717 DOI: 10.1177/0091270005280851 |
0.393 |
|
| 2004 |
Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. Journal of Clinical Pharmacology. 44: 1132-42. PMID 15342614 DOI: 10.1177/0091270004269521 |
0.344 |
|
| 2004 |
Kim MJ, Nafziger AN, Zhang Y, Sellers EM, Gaedigk A, Bertino JS. Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. Journal of Clinical Pharmacology. 44: 966-73. PMID 15317824 DOI: 10.1177/0091270004268910 |
0.327 |
|
| 2004 |
Mamo D, Sedman E, Tillner J, Sellers EM, Romach MK, Kapur S. EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. Psychopharmacology. 175: 382-8. PMID 15007535 DOI: 10.1007/S00213-004-1817-7 |
0.324 |
|
| 2003 |
Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 5: 891-9. PMID 14668073 DOI: 10.1080/14622200310001615231 |
0.333 |
|
| 2003 |
Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clinical Pharmacology and Therapeutics. 74: 437-47. PMID 14586384 DOI: 10.1016/S0009-9236(03)00229-7 |
0.341 |
|
| 2003 |
Spies CD, Otter HE, Hüske B, Sinha P, Neumann T, Rettig J, Lenzenhuber E, Kox WJ, Sellers EM. Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. Intensive Care Medicine. 29: 2230-8. PMID 14557857 DOI: 10.1007/S00134-003-2033-3 |
0.307 |
|
| 2003 |
Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. Journal of Clinical Psychopharmacology. 23: 269-80. PMID 12826989 DOI: 10.1097/01.Jcp.0000084031.22282.24 |
0.672 |
|
| 2003 |
Howard LA, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics. 13: 321-8. PMID 12777962 DOI: 10.1097/00008571-200306000-00003 |
0.325 |
|
| 2003 |
Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 768-72. PMID 12756210 DOI: 10.1124/Dmd.31.6.768 |
0.355 |
|
| 2003 |
Micu AL, Miksys S, Sellers EM, Koop DR, Tyndale RF. Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. The Journal of Pharmacology and Experimental Therapeutics. 306: 941-7. PMID 12750430 DOI: 10.1124/Jpet.103.052183 |
0.337 |
|
| 2003 |
Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Molecular Pharmacology. 63: 96-104. PMID 12488541 DOI: 10.1124/Mol.63.1.96 |
0.304 |
|
| 2002 |
Kim MJ, Bertino JS, Gaedigk A, Zhang Y, Sellers EM, Nafziger AN. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clinical Pharmacology and Therapeutics. 72: 192-9. PMID 12189366 DOI: 10.1067/Mcp.2002.126174 |
0.335 |
|
| 2002 |
Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochemical Pharmacology. 63: 2111-9. PMID 12110370 DOI: 10.1016/S0006-2952(02)01028-6 |
0.348 |
|
| 2002 |
Zhang W, Ramamoorthy Y, Tyndale RF, Glick SD, Maisonneuve IM, Kuehne ME, Sellers EM. Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 663-9. PMID 12019193 DOI: 10.1124/Dmd.30.6.663 |
0.304 |
|
| 2002 |
Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, Sellers EM. Designer drugs that are potent inhibitors of CYP2D6. Journal of Clinical Psychopharmacology. 22: 330-2. PMID 12006905 DOI: 10.1097/00004714-200206000-00015 |
0.377 |
|
| 2002 |
Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. Journal of Clinical Psychopharmacology. 22: 326-9. PMID 12006904 DOI: 10.1097/00004714-200206000-00014 |
0.344 |
|
| 2002 |
Howard LA, Sellers EM, Tyndale RF. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics. 3: 185-99. PMID 11972441 DOI: 10.1517/14622416.3.2.185 |
0.391 |
|
| 2001 |
Schoedel KA, Sellers EM, Tyndale RF. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochemical Pharmacology. 62: 1025-36. PMID 11597571 DOI: 10.1016/S0006-2952(01)00744-4 |
0.319 |
|
| 2001 |
Ramamoorthy Y, Tyndale RF, Sellers EM. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 11: 477-87. PMID 11505218 DOI: 10.1097/00008571-200108000-00003 |
0.369 |
|
| 2000 |
Busto UE, Kaplan HL, Wright CE, Gomez-Mancilla B, Zawertailo L, Greenblatt DJ, Sellers EM. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. Journal of Clinical Psychopharmacology. 20: 628-35. PMID 11106134 DOI: 10.1097/00004714-200012000-00008 |
0.671 |
|
| 2000 |
Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM. Comparative abuse liability of intravenously administered remifentanil and fentanyl Journal of Clinical Psychopharmacology. 20: 597-606. PMID 11106130 DOI: 10.1097/00004714-200012000-00002 |
0.439 |
|
| 2000 |
Kathiramalainathan K, Kaplan HL, Romach MK, Busto UE, Li NY, Säwe J, Tyndale RF, Sellers EM. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. Journal of Clinical Psychopharmacology. 20: 435-44. PMID 10917405 DOI: 10.1097/00004714-200008000-00008 |
0.398 |
|
| 2000 |
Sellers EM, Tyndale RF. Mimicking gene defects to treat drug dependence. Annals of the New York Academy of Sciences. 909: 233-46. PMID 10911933 DOI: 10.1111/J.1749-6632.2000.Tb06685.X |
0.374 |
|
| 2000 |
Kilicarslan T, Sellers EM. Lack of interaction of buprenorphine with flunitrazepam metabolism. The American Journal of Psychiatry. 157: 1164-6. PMID 10873929 DOI: 10.1176/Appi.Ajp.157.7.1164 |
0.318 |
|
| 2000 |
Romach MK, Otton SV, Somer G, Tyndale RF, Sellers EM. Cytochrome P450 2D6 and treatment of codeine dependence. Journal of Clinical Psychopharmacology. 20: 43-5. PMID 10653207 DOI: 10.1097/00004714-200002000-00008 |
0.373 |
|
| 2000 |
Romach MK, Sellers EM, Kaplan HL, Somer GR, Gomez-Mancilla B. Efficacy of Dexfenfluramine in the Treatment of Alcohol Dependence Alcoholism: Clinical and Experimental Research. 24: 1534-1541. DOI: 10.1111/J.1530-0277.2000.Tb04572.X |
0.364 |
|
| 1999 |
Busto UE, Zawertailo LA, Kaplan HL, Sellers EM. Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing. The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 6: 103-10. PMID 10519736 |
0.61 |
|
| 1999 |
Sproule BA, Busto UE, Somer G, Romach MK, Sellers EM. Characteristics of dependent and nondependent regular users of codeine Journal of Clinical Psychopharmacology. 19: 367-372. PMID 10440466 DOI: 10.1097/00004714-199908000-00014 |
0.329 |
|
| 1999 |
Lelas S, Wegert S, Otton SV, Sellers EM, France CP. Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug and Alcohol Dependence. 54: 239-49. PMID 10372797 DOI: 10.1016/S0376-8716(98)00169-0 |
0.343 |
|
| 1998 |
Chow BL, Sellers EM, Tomkins DM. Effect of naltrexone and its derivatives, nalmefene and naltrindole, on conditioned anticipatory behaviour and saccharin intake in rats. Behavioural Pharmacology. 8: 725-35. PMID 9832959 DOI: 10.1097/00008877-199712000-00008 |
0.36 |
|
| 1998 |
Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. Journal of Clinical Psychopharmacology. 18: 332-7. PMID 9690700 DOI: 10.1097/00004714-199808000-00014 |
0.637 |
|
| 1998 |
Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. Journal of Clinical Psychopharmacology. 18: 198-207. PMID 9617978 DOI: 10.1097/00004714-199806000-00004 |
0.395 |
|
| 1998 |
Romach MK, Kaplan HL, Busto UE, Somer G, Sellers EM. A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation Journal of Clinical Psychopharmacology. 18: 121-131. PMID 9555597 DOI: 10.1097/00004714-199804000-00004 |
0.323 |
|
| 1998 |
Ozdemir V, Naranjo CA, Herrmann N, Shulman RW, Sellers EM, Reed K, Kalow W. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. Journal of Clinical Psychopharmacology. 18: 55-61. PMID 9472843 DOI: 10.1097/00004714-199802000-00009 |
0.379 |
|
| 1998 |
Buczek Y, Le AD, Sellers EM, Tomkins DM. Effect of Pentylenetetrazole on Ethanol Intake, Ethanol Kinetics, and Social Behavior in Male Wistar Rats Alcoholism: Clinical and Experimental Research. 22: 428-436. DOI: 10.1111/J.1530-0277.1998.Tb03670.X |
0.321 |
|
| 1997 |
Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics. 7: 375-9. PMID 9352573 DOI: 10.1097/00008571-199710000-00006 |
0.344 |
|
| 1997 |
Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochemical Pharmacology. 53: 1605-12. PMID 9264312 DOI: 10.1016/S0006-2952(97)00014-2 |
0.317 |
|
| 1996 |
Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6 British Journal of Clinical Pharmacology. 41: 149-156. PMID 8838442 DOI: 10.1111/J.1365-2125.1996.Tb00173.X |
0.309 |
|
| 1996 |
Busto UE, Romach MK, Sellers EM. Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence Journal of Clinical Psychopharmacology. 16: 51-57. PMID 8834419 DOI: 10.1097/00004714-199602000-00009 |
0.349 |
|
| 1996 |
LE AD, TOMKINS DM, SELLERS EM. USE OF SEROTONIN (5-HT) AND OPIATE-BASED DRUGS IN THE PHARMACOTHERAPY OF ALCOHOL DEPENDENCE: AN OVERVIEW OF THE PRECLINICAL DATA Alcohol and Alcoholism. 31: 27-32. DOI: 10.1093/Oxfordjournals.Alcalc.A008215 |
0.309 |
|
| 1995 |
Joharchi N, Sellers EM, Higgins GA. Effect of 5-HT3 receptor antagonists on the discriminative stimulus properties of morphine in rats. Psychopharmacology. 112: 111-5. PMID 7870998 DOI: 10.1007/Bf02247370 |
0.323 |
|
| 1995 |
Higgins GA, Wang Y, Corrigall WA, Sellers EM. Influence of 5-HT3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. Psychopharmacology. 114: 611-9. PMID 7855223 DOI: 10.1007/Bf02244992 |
0.324 |
|
| 1995 |
Zawertailo LA, Busto U, Kaplan HL, Sellers EM. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. Journal of Clinical Psychopharmacology. 15: 117-24. PMID 7782484 DOI: 10.1097/00004714-199504000-00007 |
0.667 |
|
| 1995 |
Romach M, Busto U, Somer G, Kaplan HL, Sellers E. Clinical aspects of chronic use of alprazolam and lorazepam American Journal of Psychiatry. 152: 1161-1167. PMID 7625464 DOI: 10.1176/Ajp.152.8.1161 |
0.329 |
|
| 1995 |
Tomkins DM, Le AD, Sellers EM. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology. 117: 479-485. PMID 7604151 DOI: 10.1007/Bf02246222 |
0.321 |
|
| 1995 |
Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. Journal of Clinical Psychopharmacology. 15: 263-9. PMID 7593709 DOI: 10.1097/00004714-199508000-00005 |
0.364 |
|
| 1994 |
Busto U, Kaplan HL, Zawertailo L, Sellers EM. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans Clinical Pharmacology and Therapeutics. 55: 451-463. PMID 8162672 DOI: 10.1038/Clpt.1994.55 |
0.659 |
|
| 1994 |
Higgins GA, Tomkins DM, Poulos CX, Sellers EM. Effect of dexfenfluramine on saccharin drinking: behavioural and pharmacological studies. Pharmacology, Biochemistry, and Behavior. 47: 307-15. PMID 8146222 DOI: 10.1016/0091-3057(94)90015-9 |
0.337 |
|
| 1994 |
Higgins GA, Sellers EM. Antagonist-precipitated opioid withdrawal in rats: evidence for dissociations between physical and motivational signs. Pharmacology, Biochemistry, and Behavior. 48: 1-8. PMID 8029278 DOI: 10.1016/0091-3057(94)90489-8 |
0.314 |
|
| 1994 |
Higgins GA, Joharchi N, Wang Y, Corrigall WA, Sellers EM. The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol. Brain Research. 640: 246-54. PMID 8004452 DOI: 10.1016/0006-8993(94)91880-5 |
0.34 |
|
| 1994 |
Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence Alcoholism: Clinical and Experimental Research. 18: 879-885. PMID 7978099 DOI: 10.1111/J.1530-0277.1994.Tb00054.X |
0.341 |
|
| 1993 |
Wu D, Otton S, Sproule B, Busto U, Inaba T, Kalow W, Sellers E. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone British Journal of Clinical Pharmacology. 35: 30-34. PMID 8448065 DOI: 10.1111/J.1365-2125.1993.Tb05666.X |
0.385 |
|
| 1993 |
Higgins GA, Wang Y, Sellers EM. Preliminary findings with the indirect 5-HT agonist dexfenfluramine on heroin discrimination and self-administration in rats. Pharmacology, Biochemistry, and Behavior. 45: 963-6. PMID 8415837 DOI: 10.1016/0091-3057(93)90148-M |
0.346 |
|
| 1993 |
Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone Clinical Pharmacology and Therapeutics. 54: 463-472. PMID 7693389 DOI: 10.1038/Clpt.1993.177 |
0.319 |
|
| 1992 |
Higgins GA, Nguyen P, Sellers EM. Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists Brain Research. 572: 208-215. PMID 1611514 DOI: 10.1016/0006-8993(92)90471-K |
0.337 |
|
| 1992 |
Higgins GA, Nguyen P, Sellers EM. The NMDA antagonist dizocilpine (MK801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal Life Sciences. 50: PL167-PL172. PMID 1533700 DOI: 10.1016/0024-3205(92)90452-U |
0.317 |
|
| 1992 |
Higgins GA, Joharchi N, Nguyen P, Sellers EM. Effect of the 5-HT3 receptor antagonists, MDL72222 and ondansetron on morphine place conditioning Psychopharmacology. 106: 315-320. PMID 1533288 DOI: 10.1007/Bf02245411 |
0.328 |
|
| 1992 |
Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL, Sellers EM. Characteristics of long-term alprazolam users in the community. Journal of Clinical Psychopharmacology. 12: 316-21. PMID 1479048 DOI: 10.1097/00004714-199210000-00004 |
0.308 |
|
| 1992 |
SULLIVAN JT, SELLERS EM. Detoxification for Triazolam Physical Dependence Journal of Clinical Psychopharmacology. 12: 124???127. DOI: 10.1097/00004714-199204000-00008 |
0.387 |
|
| 1992 |
SELLERS EM, SCHNEIDERMAN JF, ROMACH MK, KAPLAN HL, SOMER GR. Comparative Drug Effects and Abuse Liability of Lorazepam, Buspirone, and Secobarbital in Nondependent Subjects Journal of Clinical Psychopharmacology. 12: 79???85. DOI: 10.1097/00004714-199204000-00002 |
0.424 |
|
| 1991 |
Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics. Clinical Pharmacology and Therapeutics. 50: 96-106. PMID 1855357 DOI: 10.1038/Clpt.1991.108 |
0.348 |
|
| 1991 |
Higgins GA, Nguyen P, Joharchi N, Sellers EM. Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal Psychopharmacology. 105: 322-328. PMID 1839177 DOI: 10.1007/Bf02244425 |
0.322 |
|
| 1991 |
Sellers EM, Otton SV, Busto UE. Drug metabolism and interactions in abuse liability assessment British Journal of Addiction. 86: 1607-1614. PMID 1786494 DOI: 10.1111/J.1360-0443.1991.Tb01755.X |
0.404 |
|
| 1991 |
Busto UE, Sellers EM. Anxiolytics and sedative/hypnotics dependence British Journal of Addiction. 86: 1647-1652. PMID 1686199 DOI: 10.1111/J.1360-0443.1991.Tb01760.X |
0.385 |
|
| 1991 |
Busto U, Sellers EM. Pharmacologic aspects of benzodiazepine tolerance and dependence Journal of Substance Abuse Treatment. 8: 29-33. PMID 1675689 DOI: 10.1016/0740-5472(91)90024-5 |
0.365 |
|
| 1990 |
Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM. Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans European Journal of Clinical Pharmacology. 38: 165-169. PMID 2338114 DOI: 10.1007/Bf00265978 |
0.317 |
|
| 1990 |
Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clinical Pharmacology and Therapeutics. 47: 490-8. PMID 2328557 DOI: 10.1038/Clpt.1990.62 |
0.34 |
|
| 1990 |
Bendayan R, Sellers EM, Silverman M. Inhibition kinetics of cationic drugs on N'-methylnicotinamide uptake by brush border membrane vesicles from the dog kidney cortex. Canadian Journal of Physiology and Pharmacology. 68: 467-75. PMID 2139353 DOI: 10.1139/Y90-066 |
0.316 |
|
| 1989 |
Sellers EM, Kadlec KE, Kaplan HL, Naranjo CA. Limitations in the measurement of urine ethanol in clinical trials to monitor ethanol consumption. Journal of Studies On Alcohol. 49: 567-70. PMID 2976866 DOI: 10.15288/Jsa.1988.49.567 |
0.347 |
|
| 1989 |
Sullivan JT, Naranjo CA, Shaw CA, Kaplan HL, Kadlec KE, Sellers EM. Kinetic and dynamic interactions of oral viqualine and ethanol in man European Journal of Clinical Pharmacology. 36: 93-96. PMID 2917597 DOI: 10.1007/Bf00561033 |
0.338 |
|
| 1989 |
Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clinical Pharmacology and Therapeutics. 46: 301-9. PMID 2673621 DOI: 10.1038/Clpt.1989.142 |
0.374 |
|
| 1989 |
Busto UE, Kathy S, Sellers EM. A clinical scale to assess benzodiazepine withdrawal Journal of Clinical Psychopharmacology. 9: 412-416. PMID 2574193 DOI: 10.1097/00004714-198912000-00005 |
0.355 |
|
| 1989 |
Busto U, Bendayan R, Sellers EM. Clinical Pharmacokinetics of Non-Opiate Abused Drugs Clinical Pharmacokinetics. 16: 1-26. PMID 2565176 DOI: 10.2165/00003088-198916010-00001 |
0.395 |
|
| 1989 |
Shaw CA, Sullivan JT, Kadlec KE, Kaplan HL, Naranjo CA, Sellers EM. Ethanol interactions with serotonin uptake selective and non-selective antidepressants: Fluoxetine and amitriptyline Human Psychopharmacology: Clinical and Experimental. 4: 113-120. DOI: 10.1002/Hup.470040206 |
0.322 |
|
| 1988 |
Sullivan JT, Naranjo CA, Sellers EM. Compliance among heavy alcohol users in clinical drug trials Journal of Substance Abuse. 1: 183-194. PMID 2980999 DOI: 10.1016/S0899-3289(88)80021-X |
0.392 |
|
| 1988 |
SHAW CA, SELLERS EM, SULLIVAN JT, KAPLAN HL. Comparative Neurologic Effects of Diazepam and Suriclone, a Cyclopyrrolone Anxiolytic Journal of Clinical Psychopharmacology. 8: 189???192. DOI: 10.1097/00004714-198806000-00006 |
0.343 |
|
| 1988 |
Sellers E, Naranjo C. Interaction of serotonin uptake inhibitors with ethanol Drug and Alcohol Review. 7: 113-116. DOI: 10.1080/09595238880000251 |
0.328 |
|
| 1988 |
Naranjo CA, Sellers EM. Serotonin uptake inhibitors attenuate ethanol intake in humans Drug and Alcohol Review. 7: 109-112. DOI: 10.1080/09595238880000241 |
0.359 |
|
| 1987 |
Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clinical Pharmacology and Therapeutics. 41: 266-74. PMID 3469057 DOI: 10.1038/Clpt.1987.27 |
0.356 |
|
| 1987 |
Cappell H, Busto U, Kay G, Naranjo CA, Sellers EM, Sanchez-Craig M. Drug deprivation and reinforcement by diazepam in a dependent population Psychopharmacology. 91: 154-160. PMID 3107027 DOI: 10.1007/Bf00217055 |
0.378 |
|
| 1987 |
SELLERS EM, NARANJO CA, KADLEC K. Do Serotonin Uptake Inhibitors Decrease Smoking? Observations in a Group of Heavy Drinkers Journal of Clinical Psychopharmacology. 7: 417???419. DOI: 10.1097/00004714-198712000-00009 |
0.34 |
|
| 1986 |
Busto U, Sellers EM. Pharmacokinetic Determinants of Drug Abuse and Dependence: A Conceptual Perspective Clinical Pharmacokinetics. 11: 144-153. PMID 3514044 DOI: 10.2165/00003088-198611020-00004 |
0.394 |
|
| 1986 |
Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines New England Journal of Medicine. 315: 854-859. PMID 3092053 DOI: 10.1056/Nejm198610023151403 |
0.343 |
|
| 1986 |
Busto U, Sellers EM, Naranjo CA, Cappell HD, Sanchez-Craig M, Simpkins J. Patterns of benzodiazepine abuse and dependence British Journal of Addiction. 81: 87-94. PMID 2870731 DOI: 10.1111/J.1360-0443.1986.Tb00299.X |
0.429 |
|
| 1986 |
Sullivan JT, Sellers EM. Treatment of the barbiturate abstinence syndrome* Medical Journal of Australia. 145: 456-458. DOI: 10.5694/J.1326-5377.1986.Tb113873.X |
0.34 |
|
| 1985 |
Kaplan HL, Sellers EM, Hamilton C, Naranjo CA, Dorian P. Is there acute tolerance to alcohol at steady state? Journal of Studies On Alcohol. 46: 253-6. PMID 4010303 DOI: 10.15288/Jsa.1985.46.253 |
0.325 |
|
| 1985 |
Dorian P, Sellers EM, Kaplan HL, Hamilton C, Greenblatt DJ, Abernethy D. Triazolam and ethanol interaction: kinetic and dynamic consequences. Clinical Pharmacology and Therapeutics. 37: 558-62. PMID 2859136 DOI: 10.1038/Clpt.1985.88 |
0.338 |
|
| 1984 |
Dorian P, Sellers EM, Kaplan H, Hamilton C. Evaluation of zopiclone physical dependence liability in normal volunteers. Pharmacology. 228-34. PMID 6669632 DOI: 10.1159/000137931 |
0.337 |
|
| 1984 |
Dorian P, Sellers EM, Kaplan HL, Carruthers G, Hamilton C, Khouw V. Ethanol-induced inhibition of hepatic uptake of propranolol in perfused rat liver and in man. European Journal of Clinical Pharmacology. 27: 209-15. PMID 6499899 DOI: 10.1007/Bf00544047 |
0.3 |
|
| 1984 |
Harrison M, Busto U, Naranjo CA, Kaplan HL, Sellers EM. Diazepam tapering in detoxification for high-dose benzodiazepine abuse Clinical Pharmacology and Therapeutics. 36: 527-533. PMID 6434221 DOI: 10.1038/Clpt.1984.214 |
0.408 |
|
| 1984 |
Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clinical Pharmacology and Therapeutics. 35: 374-81. PMID 6230195 DOI: 10.1038/Clpt.1984.46 |
0.35 |
|
| 1983 |
Naranjo CA, Sellers EM, Chater K, Iversen P, Roach C, Sykora K. Nonpharmacologic intervention in acute alcohol withdrawal. Clinical Pharmacology and Therapeutics. 34: 214-9. PMID 6872416 DOI: 10.1038/Clpt.1983.155 |
0.392 |
|
| 1983 |
Sandor P, Naranjo CA, Khouw V, Sellers EM. Variations in drug free fraction during alcohol withdrawal. British Journal of Clinical Pharmacology. 15: 481-6. PMID 6849785 DOI: 10.1111/J.1365-2125.1983.Tb01533.X |
0.403 |
|
| 1983 |
Sellers EM, Sandor P, Giles HG, Khouw V, Greenblatt DJ. Diazepam pharmacokinetics after intravenous administration in alcohol withdrawal. British Journal of Clinical Pharmacology. 15: 125-7. PMID 6849737 DOI: 10.1111/J.1365-2125.1983.Tb01478.X |
0.321 |
|
| 1983 |
Long JP, Giles HG, Bennett J, Dorian P, Thiessen JJ, Orrego H, Sellers EM. Effect of alcohol on propylthiouracil disposition. Clinical Pharmacology and Therapeutics. 33: 663-7. PMID 6839636 DOI: 10.1038/Clpt.1983.90 |
0.362 |
|
| 1983 |
Sellers EM, Naranjo CA, Harrison M, Devenyi P, Roach C, Sykora K. Diazepam loading: simplified treatment of alcohol withdrawal. Clinical Pharmacology and Therapeutics. 34: 822-6. PMID 6641099 DOI: 10.1038/Clpt.1983.256 |
0.368 |
|
| 1983 |
Dorian P, Sellers EM, Reed KL, Warsh JJ, Hamilton C, Kaplan HL, Fan T. Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. European Journal of Clinical Pharmacology. 25: 325-31. PMID 6628520 DOI: 10.1007/Bf01037943 |
0.321 |
|
| 1983 |
Sellers EM, Frecker RC, Romach MK. Drug metabolism in the elderly: confounding of age, smoking, and ethanol effects. Drug Metabolism Reviews. 14: 225-50. PMID 6341026 DOI: 10.3109/03602538308991390 |
0.326 |
|
| 1983 |
Busto U, Simpkins J, Sellers EM, Sisson B, Segal R. Objective determination of benzodiazepine use and abuse in alcoholics British Journal of Addiction. 78: 429-435. PMID 6140937 DOI: 10.1111/J.1360-0443.1983.Tb02531.X |
0.353 |
|
| 1982 |
Giles HG, Roberts EA, Orrego H, Sellers EM. Disposition of intravenous propylthiouracil. Journal of Clinical Pharmacology. 21: 466-71. PMID 7334138 DOI: 10.1002/J.1552-4604.1981.Tb05651.X |
0.357 |
|
| 1982 |
Giles HG, Corrigall WA, Khouw V, Sellers EM. Plasma protein binding of phencyclidine. Clinical Pharmacology and Therapeutics. 31: 77-82. PMID 7053308 DOI: 10.1038/Clpt.1982.12 |
0.333 |
|
| 1982 |
Naranjo CA, Busto U, Sellers EM. Difficulties in assessing adverse drug reactions in clinical trials Progress in Neuropsychopharmacology and Biological Psychiatry. 6: 651-657. PMID 6761768 DOI: 10.1016/S0278-5846(82)80162-0 |
0.348 |
|
| 1982 |
Naranjo CA, Fornazzari L, Sellers EM. Clinical detection and assessment of drug induced neurotoxicity. Progress in Neuro-Psychopharmacology. 5: 427-34. PMID 6280224 DOI: 10.1016/0364-7722(81)90024-2 |
0.358 |
|
| 1982 |
Sellers EM, Busto U. Benzodiazepines and ethanol: Assessment of the effects and consequences of psychotropic drug interactions Journal of Clinical Psychopharmacology. 2: 249-262. PMID 6126493 DOI: 10.1097/00004714-198208000-00004 |
0.325 |
|
| 1982 |
Sellers EM. Alcohol and drug dependence: Trends in Pharmacological Sciences. 3: 450-452. DOI: 10.1016/0165-6147(82)91226-3 |
0.345 |
|
| 1981 |
Sellers EM, Naranjo CA, Giles HG, Frecker RC, Beeching M. Intravenous diazepam and oral ethanol interaction. Clinical Pharmacology and Therapeutics. 28: 638-45. PMID 7438683 DOI: 10.1038/Clpt.1980.215 |
0.368 |
|
| 1981 |
Busto U, Kaplan HL, Sellers EM. Age- and sex-related differences in patterns of drug overdose and abuse Social Science and Medicine. Part E Medical Psychology. 15: 275-282. PMID 7323849 DOI: 10.1016/0271-5384(81)90003-X |
0.336 |
|
| 1981 |
Jacob MS, Carlen PL, Marshman JA, Sellers EM. Phencyclidine ingestion: drug abuse and psychosis. The International Journal of the Addictions. 16: 749-58. PMID 7287252 DOI: 10.3109/10826088109038866 |
0.364 |
|
| 1981 |
Giles HG, Sellers EM, Naranjo CA, Frecker RC, Greenblatt DJ. Disposition of intravenous diazepam in young men and women. European Journal of Clinical Pharmacology. 20: 207-13. PMID 7286038 DOI: 10.1007/Bf00544599 |
0.307 |
|
| 1981 |
Sellers EM, Busto U, Marshman JA. Acute and chronic drug abuse emergencies in metropolitan Toronto International Journal of the Addictions. 16: 283-303. PMID 7275381 DOI: 10.3109/10826088109038829 |
0.368 |
|
| 1981 |
Sandor P, Sellers EM, Dumbrell M, Khouw V. Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Clinical Pharmacology and Therapeutics. 30: 390-7. PMID 7273603 DOI: 10.1038/Clpt.1981.178 |
0.363 |
|
| 1981 |
Robinson GM, Sellers EM, Janecek E. Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique. Clinical Pharmacology and Therapeutics. 30: 71-6. PMID 7237901 DOI: 10.1038/Clpt.1981.129 |
0.335 |
|
| 1981 |
Naranjo CA, Cappell H, Sellers EM. Pharmacological control of alcohol consumption: tactics for the identification and testing of new drugs. Addictive Behaviors. 6: 261-9. PMID 7027758 DOI: 10.1016/0306-4603(81)90024-1 |
0.358 |
|
| 1981 |
Sellers EM, Naranjo CA, Peachey JE. Drug therapy: Drugs to decrease alcohol consumption. The New England Journal of Medicine. 305: 1255-62. PMID 7027044 DOI: 10.1056/Nejm198111193052105 |
0.335 |
|
| 1980 |
Korey A, Zilm DH, Sellers EM. Dependence liability of two antidiarrheals, nufenoxole and loperamide. Clinical Pharmacology and Therapeutics. 27: 659-64. PMID 7371363 DOI: 10.1038/Clpt.1980.93 |
0.375 |
|
| 1980 |
Kaplan HL, Sellers EM, Marshman JA, Giles HG, MacLeod SM, Kapur BM, Stapleton C, Sealey F, Busto U. Alcohol use by patients admitted to hospital emergency rooms for treatment of drug overdose and misuse Journal of Studies On Alcohol. 41: 882-893. PMID 7206719 DOI: 10.15288/Jsa.1980.41.882 |
0.322 |
|
| 1980 |
Giles HG, Miller R, Macleod SM, Sellers EM. Diazepam and N-desmethyldiazepam in saliva of hospital inpatients. Journal of Clinical Pharmacology. 20: 71-6. PMID 6769976 DOI: 10.1002/J.1552-4604.1980.Tb02528.X |
0.332 |
|
| 1980 |
Naranjo CA, Sellers EM, Giles HG, Abel JG. Diurnal variations in plasma diazepam concentrations associated with reciprocal changes in free fraction. British Journal of Clinical Pharmacology. 9: 265-72. PMID 6767493 DOI: 10.1111/J.1365-2125.1980.Tb04836.X |
0.324 |
|
| 1979 |
Zilm DH, Sellers EM. The quantitative assessment of physical dependence on opiates. Drug and Alcohol Dependence. 3: 419-28. PMID 720211 DOI: 10.1016/0376-8716(78)90014-5 |
0.334 |
|
| 1979 |
Beattie BL, Sellers EM. Psychoactive drug use in the elderly: the pharmacokinetics. Psychosomatics. 20: 474-9. PMID 493473 DOI: 10.1016/S0033-3182(79)70788-2 |
0.333 |
|
| 1979 |
Martin PR, Bhushan CM, Kapur BM, Whiteside EA, Sellers EM. Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: a kinetic approach. Clinical Pharmacology and Therapeutics. 26: 256-64. PMID 455894 DOI: 10.1002/Cpt1979262256 |
0.303 |
|
| 1979 |
Sellers EM, Greenblatt DJ, Giles HG, Naranjo CA, Kaplan H, MacLeod SM. Chlordiazepoxide and oxazepam disposition in cirrhosis. Clinical Pharmacology and Therapeutics. 26: 240-6. PMID 455893 DOI: 10.1002/Cpt1979262240 |
0.326 |
|
| 1979 |
Sellers EM, Holloway MR. Drug kinetics and alcohol ingestion. Clinical Pharmacokinetics. 3: 440-52. PMID 31257 DOI: 10.2165/00003088-197803060-00002 |
0.403 |
|
| 1978 |
Sellers EM, Greenblatt DJ, Zilm DH, Degani N. Decline in chlordiazepoxide plasma levels during fixed-dose therapy of alcohol withdrawal. British Journal of Clinical Pharmacology. 6: 370-2. PMID 698032 DOI: 10.1111/J.1365-2125.1978.Tb00867.X |
0.301 |
|
| 1978 |
Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM, Franke K, Giles HG. Absorption of oral and intramuscular chlordiazepoxide. European Journal of Clinical Pharmacology. 13: 267-74. PMID 668784 DOI: 10.1007/Bf00716362 |
0.34 |
|
| 1978 |
Sellers EM. Addictive Drugs: Disposition, Tolerance, and Dependence Interrelationships Drug Metabolism Reviews. 8: 5-11. PMID 363380 DOI: 10.3109/03602537808993774 |
0.379 |
|
| 1978 |
Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM. Clinical pharmacokinetics of chlordiazepoxide. Clinical Pharmacokinetics. 3: 381-94. PMID 359214 DOI: 10.2165/00003088-197803050-00004 |
0.336 |
|
| 1978 |
MacLeod SM, Sellers EM, Giles HG, Billings BJ, Martin PR, Greenblatt DJ, Marshman JA. Interaction of disulfiram with benzodiazepines. Clinical Pharmacology and Therapeutics. 24: 583-9. PMID 29739 DOI: 10.1002/Cpt1978245583 |
0.395 |
|
| 1977 |
MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM. Diazepam actions and plasma concentrations following ethanol ingestion. European Journal of Clinical Pharmacology. 11: 345-9. PMID 880973 DOI: 10.1007/Bf00566531 |
0.356 |
|
| 1977 |
Zsotér TT, Sellers EM. Effect of alcohol on cardiovascular reflexes. Journal of Studies On Alcohol. 38: 1-10. PMID 834045 DOI: 10.15288/Jsa.1977.38.1 |
0.325 |
|
| 1976 |
Koch-Weser J, Sellers EM. Binding of drugs to serum albumin (first of two parts). The New England Journal of Medicine. 294: 311-6. PMID 1107839 DOI: 10.1056/Nejm197602052940605 |
0.319 |
|
| 1976 |
Thiessen JJ, Sellers EM, Denbeigh P, Dolman L. Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. Journal of Clinical Pharmacology. 16: 345-51. PMID 947967 DOI: 10.1002/J.1552-4604.1976.Tb01531.X |
0.318 |
|
| 1976 |
MacLeod SM, Sellers EM. Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants. Drugs. 11: 461-70. PMID 782840 DOI: 10.2165/00003495-197611060-00006 |
0.36 |
|
| 1976 |
Sellers EM, Cooper SD, Zilm DH, Shanks C. Lithium treatment during alcoholic withdrawal. Clinical Pharmacology and Therapeutics. 20: 199-206. PMID 181193 DOI: 10.1002/Cpt1976202199 |
0.301 |
|
| 1976 |
Zilm DH, Sellers EM. The effect of propranolol on normal physiologic tremor. Electroencephalography and Clinical Neurophysiology. 41: 310-3. PMID 60218 DOI: 10.1016/0013-4694(76)90123-1 |
0.364 |
|
| 1976 |
SELLERS EM, THAKUR R. Partial Agonist Properties and Toxicity of Oral Oxilorphan The Journal of Clinical Pharmacology. 16: 183-188. PMID 4472 DOI: 10.1002/J.1552-4604.1976.Tb01515.X |
0.395 |
|
| 1976 |
Koch-Weser J, Sellers EM, Kalant H. Alcohol intoxication and withdrawal. The New England Journal of Medicine. 294: 757-62. PMID 3733 DOI: 10.1056/Nejm197604012941405 |
0.308 |
|
| 1971 |
Weser JK, Sellers E. Drug interactions with coumarin anticoagulants. 2. The New England Journal of Medicine. 285: 547-58. PMID 4397794 DOI: 10.1056/Nejm197109022851005 |
0.325 |
|
| 1971 |
Koch-Weser J, Sellers EM. Drug Interactions with Coumarin Anticoagulants New England Journal of Medicine. 285: 487-498. DOI: 10.1056/Nejm197108262850905 |
0.347 |
|
| Show low-probability matches. |